{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T03:14:11Z","timestamp":1785726851567,"version":"3.56.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T00:00:00Z","timestamp":1745193600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.autrev.2025.103819","type":"journal-article","created":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T15:13:02Z","timestamp":1745248382000},"page":"103819","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Janus kinase inhibitors for psoriatic arthritis: Evidence from a systematic review and network meta-analysis"],"prefix":"10.1016","volume":"24","author":[{"given":"Sotirios G.","family":"Tsiogkas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arriana","family":"Gkouvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katerina Maria","family":"Kontouli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodora","family":"Simopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria G.","family":"Grammatikopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios P.","family":"Bogdanos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2025.103819_bb0005","doi-asserted-by":"crossref","first-page":"65","DOI":"10.7861\/clinmedicine.17-1-65","article-title":"Psoriatic arthritis: state of the art review","volume":"17","author":"Coates","year":"2017","journal-title":"Clin Med (Northfield Il)"},{"key":"10.1016\/j.autrev.2025.103819_bb0010","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.jaad.2008.09.022","article-title":"The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004","volume":"60","author":"Kurd","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2025.103819_bb0015","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1001\/jamadermatol.2021.2007","article-title":"Psoriasis prevalence in adults in the United States","volume":"157","author":"Armstrong","year":"2021","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.autrev.2025.103819_bb0020","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/jdv.13854","article-title":"A systematic review of worldwide epidemiology of psoriasis","volume":"31","author":"Michalek","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.autrev.2025.103819_bb0025","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.jaad.2015.05.001","article-title":"Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: systematic review and meta-analysis","volume":"73","author":"Villani","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2025.103819_bb0030","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41572-021-00293-y","article-title":"Psoriatic arthritis","volume":"7","author":"FitzGerald","year":"2021","journal-title":"Nat Rev Dis Prim"},{"key":"10.1016\/j.autrev.2025.103819_bb0035","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/art.21972","article-title":"Classification criteria for psoriatic arthritis: development of new criteria from a large international study","volume":"54","author":"Taylor","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103819_bb0040","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","article-title":"Group for Research and Assessment of psoriasis and psoriatic arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021","volume":"18","author":"Coates","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2025.103819_bb0045","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1093\/rheumatology\/keab119","article-title":"Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis","volume":"60","author":"Mease","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2025.103819_bb0050","doi-asserted-by":"crossref","DOI":"10.1136\/ard-2024-225531","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update","author":"Gossec","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103819_bb0055","doi-asserted-by":"crossref","first-page":"S700","DOI":"10.1136\/annrheumdis-2020-217159","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update","volume":"79","author":"Gossec","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103819_bb0060","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and Cancer risk with Tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2025.103819_bb0065","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMoa2022516","article-title":"Trial of Upadacitinib and adalimumab for psoriatic arthritis","volume":"384","author":"McInnes","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2025.103819_bb0070","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1080\/13543784.2023.2207737","article-title":"Recent developments for new investigational JAK inhibitors in psoriatic arthritis","volume":"32","author":"Caso","year":"2023","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.autrev.2025.103819_bb0075","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.2147\/CCID.S433367","article-title":"JAK inhibitors in psoriatic disease","volume":"16","author":"Megna","year":"2023","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"10.1016\/j.autrev.2025.103819_bb0080","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1080\/13543784.2023.2219387","article-title":"The holistic approach to psoriasis patients with comorbidities: the role of investigational drugs","volume":"32","author":"Camela","year":"2023","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.autrev.2025.103819_bb0085","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.2147\/CCID.S423234","article-title":"Effectiveness of Brodalumab in patients with moderate-to-severe plaque psoriasis located in difficult-to-treat areas","volume":"16","author":"Cacciapuoti","year":"2023","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"10.1016\/j.autrev.2025.103819_bb0090","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","article-title":"Psoriasis","volume":"386","author":"Boehncke","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2025.103819_bb0095","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.gene.2018.09.042","article-title":"Genomic alterations driving psoriasis pathogenesis","volume":"683","author":"Singh","year":"2019","journal-title":"Gene"},{"key":"10.1016\/j.autrev.2025.103819_bb0100","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.1182\/blood-2006-10-054973","article-title":"The molecular basis of IL-21\u2013mediated proliferation","volume":"109","author":"Zeng","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2025.103819_bb0105","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/intimm\/dxt062","article-title":"Tyk2 is a therapeutic target for psoriasis-like skin inflammation","volume":"26","author":"Ishizaki","year":"2014","journal-title":"Int Immunol"},{"key":"10.1016\/j.autrev.2025.103819_bb0110","first-page":"24","article-title":"Psoriatic arthritis: pathogenesis and targeted therapies","author":"Azuaga","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.autrev.2025.103819_bb0115","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1615\/CritRevImmunol.2020033243","article-title":"Pathogenesis of psoriatic arthritis","volume":"39","author":"Caso","year":"2019","journal-title":"Crit Rev Immunol"},{"key":"10.1016\/j.autrev.2025.103819_bb0120","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s12026-013-8481-0","article-title":"JAK\/STAT\/PKC\u03b4 molecular pathways in synovial fluid T lymphocytes reflect the in vivo T helper-17 expansion in psoriatic arthritis","volume":"58","author":"Fiocco","year":"2014","journal-title":"Immunol Res"},{"key":"10.1016\/j.autrev.2025.103819_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2022.103207","article-title":"Analysis of rheumatoid- vs psoriatic arthritis synovial fluid reveals differential macrophage (CCR2) and T helper subsets (STAT3\/4 and FOXP3) activation","volume":"21","author":"Caso","year":"2022","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2025.103819_bb0130","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.autrev.2025.103819_bb0135","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"10.1016\/j.autrev.2025.103819_bb0140","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1136\/annrheumdis-2016-210242","article-title":"International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials","volume":"76","author":"Orbai","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103819_bb0145","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","article-title":"American college of rheumatology preliminary definition of improvement in rheumatoid arthritis","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103819_bb0150","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/art.1780230202","article-title":"Measurement of patient outcome in arthritis","volume":"23","author":"Fries","year":"1980","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103819_bb0155","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"Br Med J"},{"key":"10.1016\/j.autrev.2025.103819_bb0160","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/jrsm.1058","article-title":"Network meta-analysis, electrical networks and graph theory","volume":"3","author":"R\u00fccker","year":"2012","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.autrev.2025.103819_bb0165","series-title":"R: A language and environment for statistical computing","author":"R Core Team","year":"2021"},{"key":"10.1016\/j.autrev.2025.103819_bb0170","doi-asserted-by":"crossref","DOI":"10.18637\/jss.v106.i02","article-title":"Netmeta\u00a0: an R package for network Meta-analysis using frequentist methods","volume":"106","author":"Balduzzi","year":"2023","journal-title":"J Stat Softw"},{"key":"10.1016\/j.autrev.2025.103819_bb0175","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2307\/1267913","article-title":"Restricted maximum likelihood (REML) estimation of variance components in the mixed model","volume":"18","author":"Corbeil","year":"1976","journal-title":"Technometricso"},{"key":"10.1016\/j.autrev.2025.103819_bb0180","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12874-015-0060-8","article-title":"Ranking treatments in frequentist network meta-analysis works without resampling methods","volume":"15","author":"R\u00fccker","year":"2015","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.autrev.2025.103819_bb0185","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/sim.3767","article-title":"Checking consistency in mixed treatment comparison meta-analysis","volume":"29","author":"Dias","year":"2010","journal-title":"Stat Med"},{"key":"10.1016\/j.autrev.2025.103819_bb0190","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/annrheumdis-2021-221664","article-title":"Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis","volume":"81","author":"Mease","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103819_bb0195","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1002\/art.42519","article-title":"Efficacy and safety of the TYK2\/JAK1 inhibitor Brepocitinib for active psoriatic arthritis: a phase IIb randomized controlled trial","volume":"75","author":"Mease","year":"2023","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103819_bb0200","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","article-title":"Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors","volume":"377","author":"Gladman","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2025.103819_bb0205","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","article-title":"Tofacitinib or adalimumab versus placebo for psoriatic arthritis","volume":"377","author":"Mease","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2025.103819_bb0210","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1016\/S0140-6736(18)32483-8","article-title":"Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial","volume":"392","author":"Mease","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2025.103819_bb0215","first-page":"312","article-title":"Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2","volume":"80","author":"Mease","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103819_bb0220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/rmdopen-2022-002559","article-title":"Efficacy and safety of tofacitinib in Chinese patients with active psoriatic arthritis: a phase 3, randomised, double-blind, placebo-controlled study","volume":"9","author":"Leng","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.autrev.2025.103819_bb0225","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s12325-023-02732-6","article-title":"Safety of Upadacitinib in immune-mediated inflammatory diseases: systematic literature review of indirect and direct treatment comparisons of randomized controlled trials","volume":"41","author":"Mysler","year":"2024","journal-title":"Adv Ther"},{"key":"10.1016\/j.autrev.2025.103819_bb0230","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-022-10777-w","article-title":"Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database","volume":"12","author":"Hoisnard","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.autrev.2025.103819_bb0235","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1007\/s00393-021-01119-8","article-title":"Relative efficacy and safety of Janus kinase inhibitors for the treatment of active psoriatic arthritis: a network meta-analysis","volume":"82","author":"Lee","year":"2023","journal-title":"Z Rheumatol"},{"key":"10.1016\/j.autrev.2025.103819_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102902","article-title":"JAK inhibitors and psoriatic arthritis: a systematic review and meta-analysis","volume":"20","author":"Campanaro","year":"2021","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2025.103819_bb0245","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1038\/s41433-022-01943-5","article-title":"A clinician\u2019s guide to network meta-analysis","volume":"36","author":"Phillips","year":"2022","journal-title":"Eye"},{"key":"10.1016\/j.autrev.2025.103819_bb0250","author":"NCT01882439"},{"key":"10.1016\/j.autrev.2025.103819_bb0255","series-title":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of 2 Doses of Tofacitinib (CP-690,550) in Subjects with Active Psoriatic Arthritis and an Inadequate Response to at Least One TNF Inhibitor","author":"2013--001368-46","year":"2025"},{"key":"10.1016\/j.autrev.2025.103819_bb0260","article-title":"Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL broaden-a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs","volume":"5","author":"Strand","year":"2019","journal-title":"RMD Open"},{"key":"10.1016\/j.autrev.2025.103819_bb0265","series-title":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of 2 Doses of Tofacitinib (CP-690,550) or Adalimumab in Subjects With Active Psoriatic Arthritis","author":"2011--003668-55","year":"2025"},{"key":"10.1016\/j.autrev.2025.103819_bb0270","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1007\/s40744-021-00379-9","article-title":"Improvement in patient-reported outcomes in patients with psoriatic arthritis treated with Upadacitinib versus placebo or adalimumab: results from SELECT-PsA 1","volume":"8","author":"Strand","year":"2021","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.autrev.2025.103819_bb0275","author":"NCT03104400"},{"key":"10.1016\/j.autrev.2025.103819_bb0280","author":"NCT03104374"},{"key":"10.1016\/j.autrev.2025.103819_bb0285","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1007\/s40744-021-00377-x","article-title":"Patient-reported outcomes in psoriatic arthritis patients with an inadequate response to biologic disease-modifying Antirheumatic drugs: SELECT-PsA 2","volume":"8","author":"Strand","year":"2021","journal-title":"Rheumatol Ther"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997225000795?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997225000795?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T16:02:31Z","timestamp":1747152151000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997225000795"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":57,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S1568997225000795"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2025.103819","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Janus kinase inhibitors for psoriatic arthritis: Evidence from a systematic review and network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2025.103819","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103819"}}